Viral N. Shah

Glycemic Outcomes of Twiist™ Automated Insulin Delivery System in People with Diabetes Requiring Insulin, A Large Real-World Study.

BACKGROUND Automated insulin delivery (AID) systems are recommended for individuals with diabetes requiring insulin. Real-world effectiveness may differ from outcomes reported in prospective clinical trials. The twiist™ AID system recently received regulatory clearance, and real-world glycemic outcomes have not been pr...

A Multicenter 13-Week Evaluation of the twiist Automated Insulin Delivery in Insulin-Treated Type 2 Diabetes: The twiist-T2D Pivotal Trial.

Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST‐T1D Extension Study

To evaluate changes in glycaemic control following semaglutide discontinuation in adults with Type 1 diabetes and obesity who completed the ADJUST‐T1D randomised controlled trial.

Early Consideration of Automated Insulin Delivery in Type 2 Diabetes: A Critical Review.

Randomized and real-world studies demonstrate that AID systems significantly improve A1C and time in range while minimizing hypoglycemia, without increasing treatment complexity or patient burden, and position AID as a practical and effective strategy to overcome long-standing therapeutic inertia in type 2 diabetes.